Spots Global Cancer Trial Database for Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Official Title: Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)
Study ID: NCT00738751
Study Description
Brief Summary: The main purpose of the study is to: * Determine the safety and tolerability of erlotinib and LBH589B. * Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Contact Details
Name: Jhanelle Gray, M.D.
Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
